HUE062719T2 - Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások - Google Patents
Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárásokInfo
- Publication number
- HUE062719T2 HUE062719T2 HUE21207279A HUE21207279A HUE062719T2 HU E062719 T2 HUE062719 T2 HU E062719T2 HU E21207279 A HUE21207279 A HU E21207279A HU E21207279 A HUE21207279 A HU E21207279A HU E062719 T2 HUE062719 T2 HU E062719T2
- Authority
- HU
- Hungary
- Prior art keywords
- ultra
- methods
- fusion proteins
- long acting
- acting insulin
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692498P | 2018-06-29 | 2018-06-29 | |
| US201862692507P | 2018-06-29 | 2018-06-29 | |
| US201862693814P | 2018-07-03 | 2018-07-03 | |
| US201862696645P | 2018-07-11 | 2018-07-11 | |
| US201862698648P | 2018-07-16 | 2018-07-16 | |
| US201862702167P | 2018-07-23 | 2018-07-23 | |
| US201862719347P | 2018-08-17 | 2018-08-17 | |
| US201862740735P | 2018-10-03 | 2018-10-03 | |
| US201862743358P | 2018-10-09 | 2018-10-09 | |
| US201862774682P | 2018-12-03 | 2018-12-03 | |
| US201862781378P | 2018-12-18 | 2018-12-18 | |
| US201862781368P | 2018-12-18 | 2018-12-18 | |
| US201962824176P | 2019-03-26 | 2019-03-26 | |
| US201962827809P | 2019-04-01 | 2019-04-01 | |
| US201962837188P | 2019-04-22 | 2019-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE062719T2 true HUE062719T2 (hu) | 2023-11-28 |
Family
ID=68985236
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE21207279A HUE062719T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások |
| HUE21164434A HUE060471T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási módszerek |
| HUE19826154A HUE058005T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra hosszan ható inzulin Fc fehérjék, és alkalmazási eljárások |
| HUE22203969A HUE065725T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE21164434A HUE060471T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási módszerek |
| HUE19826154A HUE058005T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra hosszan ható inzulin Fc fehérjék, és alkalmazási eljárások |
| HUE22203969A HUE065725T2 (hu) | 2018-06-29 | 2019-06-28 | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US10961294B2 (hu) |
| EP (5) | EP3892628B1 (hu) |
| JP (2) | JP7417277B2 (hu) |
| KR (1) | KR20210029210A (hu) |
| CN (1) | CN113038964A (hu) |
| AU (1) | AU2019291945A1 (hu) |
| BR (1) | BR112020026777A2 (hu) |
| CA (1) | CA3104144A1 (hu) |
| DK (4) | DK4011908T5 (hu) |
| FI (2) | FI4186920T3 (hu) |
| HR (4) | HRP20230991T1 (hu) |
| HU (4) | HUE062719T2 (hu) |
| LT (4) | LT3892628T (hu) |
| SI (4) | SI3892628T1 (hu) |
| WO (1) | WO2020006529A1 (hu) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055417T2 (hu) | 2016-12-09 | 2021-11-29 | Akston Biosciences Corp | Inzulin-Fc fúziók és alkalmazási eljárások |
| EP3892628B1 (en) | 2018-06-29 | 2022-09-07 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| WO2021011827A1 (en) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| FI4073098T3 (fi) * | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| HRP20230990T1 (hr) | 2020-04-10 | 2023-12-08 | Akston Biosciences Corporation | Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| JP7532638B2 (ja) * | 2020-07-24 | 2024-08-13 | チアンスー ジェンサイエンス インコーポレイテッド | インスリン－Ｆｃ融合タンパク質及びその応用 |
| AU2021401635A1 (en) * | 2020-12-14 | 2023-06-22 | Eli Lilly And Company | Methods of treating diabetes |
| EP4373861A2 (en) | 2021-07-23 | 2024-05-29 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| WO2023064711A2 (en) * | 2021-10-14 | 2023-04-20 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| AR127619A1 (es) | 2021-11-15 | 2024-02-14 | Lilly Co Eli | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc |
| WO2023174370A1 (zh) * | 2022-03-16 | 2023-09-21 | 北京拓界生物医药科技有限公司 | 人胰岛素类似物、其融合蛋白及医药用途 |
| WO2023247640A1 (en) * | 2022-06-23 | 2023-12-28 | Sanofi | Single chain insulins and fc conjugates thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030040601A1 (en) | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
| US7169894B2 (en) * | 2001-11-14 | 2007-01-30 | Mirari Biosciences, Inc. | Methods and compositions for reverse translation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20100143479A1 (en) | 2008-12-04 | 2010-06-10 | Oakwood Laboratories, Llc | Method of making sustained release microparticles |
| US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| CA2754408A1 (en) * | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| JP2013535467A (ja) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| EP2598170A4 (en) | 2010-07-28 | 2016-07-06 | Smartcells Inc | MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES |
| AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| WO2013074598A1 (en) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| CN103509118B (zh) * | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| US10371158B2 (en) * | 2012-08-17 | 2019-08-06 | Dresser-Rand Company | System and method for detecting stall or surge in radial compressors |
| WO2014093387A1 (en) * | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| EP3616727B1 (en) | 2013-02-26 | 2021-03-31 | Hanmi Pharm. Co., Ltd. | Insulin analog conjugates and use thereof |
| EP3194429A4 (en) * | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| JP6829928B2 (ja) | 2014-10-06 | 2021-02-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 二相性単鎖インスリン類似体 |
| CA2964918A1 (en) | 2014-10-20 | 2016-04-28 | Case Western Reserve University | Halogenated insulin analogues of enhanced biological potency |
| WO2016105545A2 (en) | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| CA2974500A1 (en) | 2015-01-20 | 2016-07-28 | Case Western Reserve University | Insulin analogues with selective signaling properties and reduced mitogenicity |
| EP3250589A4 (en) * | 2015-01-29 | 2018-06-20 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
| JP2018508504A (ja) | 2015-02-17 | 2018-03-29 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続型インスリンまたはインスリンアナログ結合体 |
| WO2016164937A2 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| CN107709355B (zh) * | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | 单链cd40受体激动剂蛋白 |
| AR105616A1 (es) * | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| CN107743494B (zh) | 2015-06-02 | 2022-04-29 | 诺和诺德股份有限公司 | 具有极性重组延伸体的胰岛素 |
| EP3757119A1 (en) | 2015-11-16 | 2020-12-30 | Ubiprotein, Corp. | A method for extending half-life of a protein |
| EP3481413A4 (en) * | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| AU2017298565B2 (en) | 2016-07-22 | 2021-08-19 | The Walter And Eliza Hall Institute Of Medical Research | Insulin analogs |
| BR112019005637A2 (pt) * | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| HUE055417T2 (hu) | 2016-12-09 | 2021-11-29 | Akston Biosciences Corp | Inzulin-Fc fúziók és alkalmazási eljárások |
| AR111122A1 (es) | 2017-03-07 | 2019-06-05 | Univ Case Western Reserve | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro |
| US10572594B2 (en) | 2017-08-01 | 2020-02-25 | Intuit Inc. | Extracting domain-specific actions and entities in natural language commands recognized based on edition and recognition scores |
| JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| WO2019204206A1 (en) | 2018-04-16 | 2019-10-24 | Chou Danny Hung Chieh | Glucose-responsive insulin |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP3892628B1 (en) | 2018-06-29 | 2022-09-07 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| CA3114395A1 (en) | 2018-09-25 | 2020-04-02 | Absci, Llc | Protein purification methods |
| AR116605A1 (es) | 2018-10-05 | 2021-05-26 | Novo Nordisk As | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) |
| US20220002373A1 (en) | 2018-11-19 | 2022-01-06 | Case Western Reserve University | Single-chain insulin analogues with poly-alanine c-domain sub-segments |
| WO2020236762A2 (en) | 2019-05-17 | 2020-11-26 | Case Western Reserve University | Variant single-chain insulin analogues |
| WO2021011827A1 (en) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
-
2019
- 2019-06-28 EP EP21164434.9A patent/EP3892628B1/en active Active
- 2019-06-28 SI SI201930392T patent/SI3892628T1/sl unknown
- 2019-06-28 HR HRP20230991TT patent/HRP20230991T1/hr unknown
- 2019-06-28 LT LTEP21164434.9T patent/LT3892628T/lt unknown
- 2019-06-28 LT LTEPPCT/US2019/040010T patent/LT3655006T/lt unknown
- 2019-06-28 HU HUE21207279A patent/HUE062719T2/hu unknown
- 2019-06-28 DK DK21207279.7T patent/DK4011908T5/da active
- 2019-06-28 EP EP22203969.5A patent/EP4186920B1/en active Active
- 2019-06-28 HR HRP20220091TT patent/HRP20220091T1/hr unknown
- 2019-06-28 SI SI201930726T patent/SI4186920T1/sl unknown
- 2019-06-28 WO PCT/US2019/040010 patent/WO2020006529A1/en active Search and Examination
- 2019-06-28 EP EP23215091.2A patent/EP4344738A3/en active Pending
- 2019-06-28 EP EP19826154.7A patent/EP3655006B1/en active Active
- 2019-06-28 JP JP2020573352A patent/JP7417277B2/ja active Active
- 2019-06-28 LT LTEP21207279.7T patent/LT4011908T/lt unknown
- 2019-06-28 KR KR1020217002135A patent/KR20210029210A/ko not_active Application Discontinuation
- 2019-06-28 SI SI201930615T patent/SI4011908T1/sl unknown
- 2019-06-28 LT LTEP22203969.5T patent/LT4186920T/lt unknown
- 2019-06-28 HR HRP20221418TT patent/HRP20221418T1/hr unknown
- 2019-06-28 EP EP21207279.7A patent/EP4011908B1/en active Active
- 2019-06-28 HU HUE21164434A patent/HUE060471T2/hu unknown
- 2019-06-28 CA CA3104144A patent/CA3104144A1/en active Pending
- 2019-06-28 HU HUE19826154A patent/HUE058005T2/hu unknown
- 2019-06-28 DK DK21164434.9T patent/DK3892628T3/da active
- 2019-06-28 FI FIEP22203969.5T patent/FI4186920T3/fi active
- 2019-06-28 HR HRP20240408TT patent/HRP20240408T1/hr unknown
- 2019-06-28 DK DK19826154.7T patent/DK3655006T3/da active
- 2019-06-28 FI FIEP21207279.7T patent/FI4011908T3/fi active
- 2019-06-28 HU HUE22203969A patent/HUE065725T2/hu unknown
- 2019-06-28 DK DK22203969.5T patent/DK4186920T5/da active
- 2019-06-28 BR BR112020026777-5A patent/BR112020026777A2/pt unknown
- 2019-06-28 CN CN201980056947.5A patent/CN113038964A/zh active Pending
- 2019-06-28 SI SI201930152T patent/SI3655006T1/sl unknown
- 2019-06-28 AU AU2019291945A patent/AU2019291945A1/en active Pending
-
2020
- 2020-01-29 US US16/775,979 patent/US10961294B2/en active Active
- 2020-01-29 US US16/776,136 patent/US10947292B2/en active Active
- 2020-01-29 US US16/776,065 patent/US10870686B2/en active Active
- 2020-01-29 US US16/776,180 patent/US10851147B2/en active Active
- 2020-09-11 US US17/019,059 patent/US11261229B2/en active Active
-
2021
- 2021-09-29 US US17/488,852 patent/US11773151B2/en active Active
- 2021-09-29 US US17/488,685 patent/US11673934B2/en active Active
-
2023
- 2023-09-01 US US18/459,581 patent/US20240101635A1/en active Pending
- 2023-12-25 JP JP2023217822A patent/JP7510728B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE058005T2 (hu) | Ultra hosszan ható inzulin Fc fehérjék, és alkalmazási eljárások | |
| IL288373A (en) | flt3l-fc fusion proteins and methods of use | |
| IL279965A (en) | Unified structures and methods for their use | |
| IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
| SI4073098T1 (sl) | Ultra dolgo delujoči inzulin-fc fuzijski proteini in postopki uporabe | |
| IL267861A (en) | PD1-41BBL conjugate protein and methods of using it | |
| EP3455263A4 (en) | CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | |
| IL267862A (en) | SIRPalpha-41BBL conjugate protein and methods of using it | |
| EP3706786A4 (en) | BIS SPECIFIC FUSION POLYPEPTIDES AND METHOD OF USING THEREOF | |
| IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
| EP3600429A4 (en) | IL-37 FUSION PROTEIN AND METHODS FOR THE MANUFACTURE AND USE OF THE SAME | |
| EP3722305A4 (en) | HM-3 FUSION PROTEIN AND USES THEREOF | |
| SG11202104912SA (en) | Fusion protein and use thereof | |
| ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| EP3387019A4 (en) | RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE | |
| EP3994180A4 (en) | SIALIDASE-HER2 ANTIBODY FUSION PROTEINS AND THEIR METHODS OF USE | |
| EP3994179A4 (en) | ANTI-CD20 ANTIBODY AND SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF | |
| EP3999549A4 (en) | ANTI-PDL1 AND SIALIDASE ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF | |
| IL268234A (en) | Factor ix fusion proteins and methods of making and using same |